Healthcare Biz Recap: Carl Icahn TRASHES Forest Labs, Perrigo WINS FDA Okay
Here are Thursday’s top stories:
Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) shares move up as the firm gives an update on its leukemia drug Marqibo, announcing that its licensing partner, Talon Therapeutics, has received an accelerated FDA approval for the treatment of adult patients suffering from leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
Shares of SciClone Pharmaceuticals (NASDAQ:SCLN) pop subsequent to its second quarter bottom line exceeding Street estimates late Wednesday. Total revenue jumped 22 percent year-over-year, thanks to a 27 percent increase in sales of its drug Zadaxin, along with revenue growth from its primary care and oncology divisions in China, plus positive synergies from its recent acquisition of NovaMed Pharmaceuticals.
Carl Icahn News! The activist investor, in an open letter (as usual), now accuses Forest Laboratories, Inc. (NYSE:FRX) of conducting an ‘inadequate review’ of corporate governance reform, remarking that instead of creating an independent committee through which to select and consult with an expert in the field as promised, the firm went through a minimal process run by the entire Board and management. Icahn said the process was “a complete and utter travesty.”
Perrigo Company (NASDAQ:PRGO) announces that won a final FDA approval for its clobetasol propionate shampoo, which is the generic equivalent of Clobex Shampoo for the treatment for moderate to severe scalp psoriasis. The firm will begin shipping at once. Annual sales of the generic and branded treatment together total about $57 million.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.